Comparative Pharmacology
Head-to-head clinical analysis: VIAGRA versus YESAFILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIAGRA versus YESAFILI.
VIAGRA vs YESAFILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels in corpus cavernosum, leading to smooth muscle relaxation and blood flow into the penis.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing a conformational change leading to receptor degradation and inhibition of estrogen-dependent tumor growth.
50 mg orally once as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability. Maximum dosing frequency: once per day.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life approximately 4 hours (range 3–5 hours). No significant accumulation with recommended dosing.
Terminal elimination half-life of 3–5 hours in healthy adults; prolonged in hepatic impairment (up to 8–10 hours), requiring dose adjustment.
Renal (approximately 80% as metabolites, 20% as unchanged drug in feces), biliary/fecal (about 13% unchanged in feces). Total clearance 41 L/h.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 2% of the dose, with biliary/fecal elimination as the major route.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor